Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Oral Cladribine in Acute Myeloid Leukemia (AML)
NCT07053020Phase 2Not yet recruiting
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Dec 2027
- Primary completion
- Jun 2028
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of cladribine in acute myeloid leukemia (AML), sponsored by University of Texas MD Anderson Cancer Center. Planned start Dec 2027; status: not yet recruiting.
02
Drugs
cladribine
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT07053020.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07053020.